Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FTLF NYSE:NAVB NYSE:VNRX NASDAQ:VRML On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFTLFFitLife Brands$19.38+1.2%$16.05$9.83▼$19.39$182M0.6514,104 shs57,659 shsNAVBNavidea Biopharmaceuticals$0.00-80.0%$0.00$0.00▼$0.13$10K1.997,214 shs5,029 shsVNRXVolitionRx$0.68+9.0%$0.67$0.40▼$0.94$73.17M1.27198,353 shs501,831 shsVRMLVermillion$0.43$3.26$0.35▼$5.78$41.87M3.47440,144 shs106,092 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFTLFFitLife Brands+1.20%+9.86%+15.84%+45.50%+16.75%NAVBNavidea Biopharmaceuticals0.00%-80.00%-80.00%-50.00%-90.00%VNRXVolitionRx+8.96%+3.64%+3.00%-26.09%+10.71%VRMLVermillion+3.61%-4.42%+0.02%+160.61%-50.12%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFTLFFitLife Brands$19.38+1.2%$16.05$9.83▼$19.39$182M0.6514,104 shs57,659 shsNAVBNavidea Biopharmaceuticals$0.00-80.0%$0.00$0.00▼$0.13$10K1.997,214 shs5,029 shsVNRXVolitionRx$0.68+9.0%$0.67$0.40▼$0.94$73.17M1.27198,353 shs501,831 shsVRMLVermillion$0.43$3.26$0.35▼$5.78$41.87M3.47440,144 shs106,092 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFTLFFitLife Brands+1.20%+9.86%+15.84%+45.50%+16.75%NAVBNavidea Biopharmaceuticals0.00%-80.00%-80.00%-50.00%-90.00%VNRXVolitionRx+8.96%+3.64%+3.00%-26.09%+10.71%VRMLVermillion+3.61%-4.42%+0.02%+160.61%-50.12%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFTLFFitLife Brands 2.67Moderate Buy$23.0018.68% UpsideNAVBNavidea Biopharmaceuticals 0.00N/AN/AN/AVNRXVolitionRx 3.00Buy$3.50414.71% UpsideVRMLVermillion 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VRML, VNRX, NAVB, and FTLF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.009/4/2025FTLFFitLife BrandsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/15/2025FTLFFitLife BrandsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $25.008/15/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.007/17/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.007/9/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.00(Data available from 9/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFTLFFitLife Brands$64.47M2.82$1.01 per share19.13$3.93 per share4.93NAVBNavidea Biopharmaceuticals$8.13K1.23N/AN/AN/A∞VNRXVolitionRx$1.32M55.46N/AN/A($0.11) per share-6.18VRMLVermillion$4.54M9.22N/AN/A$0.09 per share4.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFTLFFitLife Brands$8.98M$0.8423.0717.62N/A12.63%21.70%13.45%N/ANAVBNavidea Biopharmaceuticals-$15.18MN/A0.00∞N/AN/AN/AN/AN/AVNRXVolitionRx-$35.32M-$0.25N/A∞N/A-2,321.14%N/A-163.39%N/AVRMLVermillion-$15.24MN/AN/A∞N/A-307.31%-155.25%-103.47%N/ALatest VRML, VNRX, NAVB, and FTLF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025FTLFFitLife Brands$0.18$0.18N/A$0.18$16.17 million$16.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFTLFFitLife BrandsN/AN/AN/AN/AN/ANAVBNavidea BiopharmaceuticalsN/AN/AN/AN/AN/AVNRXVolitionRxN/AN/AN/AN/AN/AVRMLVermillionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFTLFFitLife Brands0.151.710.81NAVBNavidea BiopharmaceuticalsN/AN/AN/AVNRXVolitionRxN/A0.220.22VRMLVermillion0.202.512.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFTLFFitLife Brands2.32%NAVBNavidea Biopharmaceuticals0.01%VNRXVolitionRx8.09%VRMLVermillion18.09%Insider OwnershipCompanyInsider OwnershipFTLFFitLife Brands61.40%NAVBNavidea Biopharmaceuticals43.68%VNRXVolitionRx10.40%VRMLVermillion4.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFTLFFitLife Brands209.39 million3.63 millionNot OptionableNAVBNavidea Biopharmaceuticals10100.08 million56.37 millionOptionableVNRXVolitionRx80107.60 million80.80 millionOptionableVRMLVermillion4397.38 millionN/ANot OptionableVRML, VNRX, NAVB, and FTLF HeadlinesRecent News About These CompaniesVermillion authorities investigate car vs building crashAugust 10, 2024 | keloland.comKVermillion, SD Hourly Weather ForecastApril 30, 2024 | wunderground.comWVermillion named Tree City USAApril 21, 2024 | siouxcityjournal.comSVermillion girls' basketball rallies to win Class A state titleMarch 13, 2024 | siouxcityjournal.comSPeoria police thwart school shooting; teen could be charged as an adultFebruary 18, 2024 | pjstar.comP2023 HW Vanguard: Dale VermillionOctober 15, 2023 | housingwire.comHGoodwill coming to VermillionSeptember 17, 2023 | siouxcityjournal.comSIn Telangana, Vermillion And Saffron Threads Were Used To Lure Women VotersSeptember 2, 2023 | outlookindia.comVermillion, SD 10-Day Weather ForecastJuly 17, 2023 | wunderground.comWA cold case without a crime: Inside the messy investigation into two missing SD teens in 1971June 21, 2023 | grandforksherald.comGCamellia VermillionJune 16, 2023 | health.usnews.comDr. Richard L. KnutsonJune 6, 2023 | health.usnews.comVermillion Elementary SchoolMay 24, 2023 | usnews.comDr. Kenneth J. VermillionMay 20, 2023 | health.usnews.comGolf: Vermillion Runner-Up At Huskies Invitational | Sports | plaintalk ... - Vermillion Plain TalkMay 13, 2023 | news.google.comNDriver killed after veering into path of dump truck on Highway 52 - Bring Me The NewsMay 13, 2023 | news.google.comNFatal crash in Vermillion Township closes portion of Highway 52 - CBS NewsMay 13, 2023 | news.google.comNVermillion, KS Weather ConditionsMay 13, 2023 | wunderground.comWVermillion Softball Falls To Tea Area 12-2 | Sports | plaintalk.net - Vermillion Plain TalkMay 13, 2023 | news.google.comNBaseball: Dakota Valley Blanks Vermillion 7-0 | Sports | plaintalk.net - Vermillion Plain TalkMay 13, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVRML, VNRX, NAVB, and FTLF Company DescriptionsFitLife Brands NASDAQ:FTLF$19.38 +0.23 (+1.20%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$19.27 -0.11 (-0.54%) As of 09/19/2025 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.Navidea Biopharmaceuticals NYSE:NAVB$0.0001 0.00 (-80.00%) As of 09/19/2025 12:25 PM EasternNavidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.VolitionRx NYSE:VNRX$0.68 +0.06 (+8.96%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$0.68 +0.01 (+0.74%) As of 09/19/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.Vermillion NASDAQ:VRMLVermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women. It also offers in-vitro diagnostic (IVD) trial services to third-party customers; and laboratory services to meet the needs of IVD manufacturers to commercialize high-complexity assays. The company serves clinical reference laboratories, hospital laboratories, and physician offices. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Berkshire-Backed Lennar Slides After Weak Q3 Earnings Azure Leads While AI Excitement Fuels Microsoft Stock Caterpillar Stock Hits All-Time High—Is There More Room to Run? The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
